Valsartan and body weight changes
Pro Research Analysisby 
Searched over 200M research papers
Valsartan and Body Weight Changes in Overweight and Obese Patients
Several studies have explored the effects of valsartan, an angiotensin II receptor blocker, on body weight and related metabolic parameters, particularly in overweight and obese individuals with hypertension or metabolic disorders.
Valsartan and Weight Loss in Hypertensive Patients
Research in overweight or obese patients with mild to moderate hypertension has shown that valsartan treatment can lead to significant reductions in body mass index (BMI) and body weight over a 24-week period, alongside effective blood pressure control. These patients were also advised to follow a calorie-restricted diet, which may have contributed to the observed weight loss, but the results suggest valsartan itself may play a role in supporting weight reduction in this population Villecco2004Fogari2005. Another study comparing valsartan to felodipine in obese hypertensive patients found that valsartan, but not felodipine, significantly reduced BMI and improved insulin sensitivity, indicating a potential advantage of valsartan for managing obesity-related metabolic issues .
Valsartan’s Effects in Animal Models of Obesity
Animal studies provide further insight into valsartan’s impact on body weight. In fat diet-induced obese rats, valsartan treatment improved BMI, reduced adipose tissue mass, and improved several metabolic and inflammatory markers, although it did not significantly reduce total body weight on its own. However, when combined with folic acid, valsartan contributed to a significant reduction in total body weight and further improvements in metabolic health . In a diabetic rat model, valsartan treatment led to significant increases in body weight compared to untreated diabetic rats, suggesting a protective effect against diabetes-associated weight loss, while also improving blood glucose control .
Valsartan Compared to Other ARBs and Combination Therapies
Not all angiotensin II receptor blockers have the same effect on body weight. For example, telmisartan, another ARB, was shown to increase caloric expenditure and protect against weight gain and fat accumulation in rats, whereas valsartan did not have these effects, highlighting differences within the drug class . In clinical studies, the combination of valsartan with amlodipine was effective for blood pressure control in overweight and obese hypertensive patients, but these studies did not specifically report on weight changes .
Sacubitril/Valsartan and Body Weight
Sacubitril/valsartan, a combination drug used in heart failure, has been studied for its metabolic effects. In animal models of diet-induced diabetes, sacubitril/valsartan reduced body weight and fat mass more effectively than valsartan alone . However, in clinical studies of patients with heart failure and reduced ejection fraction, sacubitril/valsartan did not significantly change body weight over time Ryu2020Kido2021. In patients undergoing peritoneal dialysis, sacubitril/valsartan was associated with improved fluid removal and a reduction in body weight, but this was likely due to fluid loss rather than fat loss .
Conclusion
Overall, valsartan may contribute to modest reductions in body weight and improvements in metabolic parameters in overweight and obese patients, especially those with hypertension. The effect appears to be more pronounced when valsartan is combined with other interventions, such as dietary changes or folic acid supplementation. In animal models, valsartan can help prevent weight loss associated with diabetes, but does not appear to increase caloric expenditure or protect against weight gain as strongly as some other ARBs like telmisartan. Combination therapies such as sacubitril/valsartan may offer additional metabolic benefits, but evidence for significant weight loss in clinical populations remains limited.
Sources and full results
Most relevant research papers on this topic